LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
MiniMed Group, the diabetes business of Medtronic, filed Tuesday to raise up to $784 million in an initial public offering. The Northridge, California-based firm p ...
InnovaMatrix revenue is expected to fall to approximately $20 million in 2026 from $69 million in 2025, a decline of roughly 71%, representing a headwind of approximately 2% of group revenue.
Everyday Health on MSN
Why 'normal' blood sugar readings don't always mean you feel good after eating
Feel tired, foggy, or irritable after eating? Learn how blood sugar spikes can happen even with a normal A1C — and what to do about them.
2d
Fart for a cause: US researchers develop ‘smart underwear’ that tracks farts to explore gut health
The scientists will develop the Human Flatus Atlas, which quantifies the dynamic range of intestinal gas production. Read ...
3don MSN
Expert reveals hidden clues in your routine blood tests that could predict cancer risk years earlier
By the time cancer symptoms appear, the disease has already been developing for years, often leaving subtle clues in routine bloodwork long before diagnosis.
Tandem Diabetes tops Q4 estimates with narrower loss, 15% revenue jump and wider gross margin, sending shares up 6.7% after hours.
Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results